Time-restricted Eating Versus Daily Continuous Calorie Restriction on Body Weight and Colorectal Cancer Risk Markers

Obesity Clinical Trial

Official title:

Effects of Time-restricted Eating Versus Daily Continuous Calorie Restriction on Body Weight and Colorectal Cancer Risk Markers Among Adults With Obesity

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05114798
• Other study ID #: 2020-1627
• Secondary ID: 1R01CA257807
• Status: Recruiting
• Phase: N/A
• Start date: May 17, 2022
• Est. completion date: September 2026

Study information

• Verified date: May 2024
• Source: University of Illinois at Chicago
• Contact: Lisa Tussing-Humphreys, PhD, MS, RD
• Phone: 312-355-5521
• Email: ltussing[@]uic.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Approximately 42% of American adults are obese, and this condition is strongly related to the development of colorectal cancer. Innovative lifestyle strategies to treat obesity and reduce colorectal cancer risk are critically needed. This research will demonstrate that time-restricted eating, a type of intermittent fasting, is an effective therapy to help obese individuals reduce and control their body weight and prevent the development of colorectal cancer.

Description:

Approximately 42% of the U.S. adult population is obese and data suggests that persons with obesity are at a 30% greater risk of developing colorectal cancer (CRC). Therefore, efficacious approaches to preventing and treating obesity will have significant effects on CRC incidence in the U.S. Although calorie restriction through lifestyle intervention is the most common approach to treat obesity, clinically meaningful weight loss is difficult to achieve via this method due to low adherence with calorie monitoring, indicating a need for innovation. Time-restricted eating, a type of intermittent fasting, has been shown in animals to impart cancer protective effects including lower body weight, decreased systemic inflammation, and improved glucose metabolism. Time-restricted eating is where individuals are asked to consume all their food for the day within a specified time frame, and water fast for the remaining hours of the day. We recently performed two short-term (≤12-weeks) pilot studies of time-restricted eating to evaluate its safety and preliminary efficacy on body weight and chronic disease risk markers in adults with obesity. Our results show the intervention is a safe and acceptable approach to weight loss among obese adults. Moreover, time-restricted eating produced approximately 3% weight loss from baseline and reductions in systolic blood pressure, oxidative stress and insulin resistance. Although these pilot findings show promise for time-restricted eating as an effective tool for CRC risk reduction among obese individuals, these data still require confirmation by a well powered longer-term clinical trial. The present proposal aims to implement a 12-month (6-month intervention, 6-month maintenance) controlled, parallel arm trial among 255 obese adults (45-70 years old) who have had a colonoscopy. Subjects will be randomized to 1 of 3 groups: 1) 8-hour time-restricted eating (daily ad libitum food intake from 12pm - 8pm), 2) Calorie restriction (daily 25% calorie restriction), or 3) Control (daily ad libitum food intake, no meal timing restrictions) to compare the effects on: (1) Body weight, body composition, and intervention adherence; (2) Circulating metabolic, inflammation, and oxidative stress-related biomarkers; (3) Colonic mucosal gene expression profiles and mucosal inflammation, DNA damage and cellular growth; and (4) maintenance of benefits on body weight/composition and CRC markers.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 255
• Est. completion date: September 2026
• Est. primary completion date: July 2026
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 45 Years to 70 Years

Eligibility

Inclusion Criteria:

1. 45-70 years old,

2. BMI 30-49.99 kg/m2

3. Are up to date with CRC screening.

Exclusion Criteria:

1. Have a history of renal disease, autoimmune disorders, immunodeficiency, malabsorptive disorder, significant gastrointestinal and hepatic disease, surgical change in gastrointestinal anatomy, severe ischemic heart disease, severe pulmonary disease, severe mental health disorder, eating disorder, or bariatric surgery;

2. Abuse alcohol (> 50 grams/day), illicit drugs (other than self-reported marijuana use), or use combustible tobacco;

3. Have controlled type 2 diabetes or undiagnosed uncontrolled diabetes based on hemoglobin A1c (HbA1c) > 9.0%;

4. Have a history of cancer treatment within the past 12 months, CRC, genetic predisposition to CRC (e.g., Lynch syndrome);

5. Have a baseline body weight > 450 lbs (weight limitation of the DXA);

6. Are on a weight loss diet or actively involved in a formal weight loss program (e.g., Weight Watchers);

7. Are not weight stable for 3 months prior to the study (weight gain or loss > 4 kg);

8. Are unable to keep a food diary for 7 consecutive days during screening;

9. Are night shift workers;

10. Are pregnant or trying to get pregnant;

11. Are taking drugs that influence study outcomes (weight loss medications);

12. Are non-English speaking

13. Are taking anticoagulant medications or medications with endoscopic risk

14. Are taking antivirals or immunosuppressant medications

15. Don't have regular access to an email address and computer/smartphone/tablet

16. Are currently following a diet that requires fasting on a weekly basis

17. Currently eat for less than 10 hours of the day (determined by asking participants what time they start and stop eating on a usual day)

Related Conditions & MeSH terms

• Body Weight
• Colorectal Cancer
• Colorectal Neoplasms
• Obesity
• Time Restricted Eating
• Weight Loss

Intervention

Behavioral:
• Time restricted eating
daily ad libitum food intake, 8-h 12pm - 8pm, 6 m active weight loss phase; 10-h 10am-8pm, 6 m maintenance phase
• Calorie Restriction
daily 25% calorie restriction, 6 m active weight loss phase; 100% energy needs, 6 m maintenance phase

Locations

Country	Name	City	State
United States	University of Illinois at Chicago	Chicago	Illinois

Sponsors (2)

Lead Sponsor	Collaborator
University of Illinois at Chicago	National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Weight change (% kg)	Body weight in kg	Baseline to month 6
Secondary	Total and regional body fat composition and distribution	Total and regional body fat composition and distribution will be measured via whole body DEXA scan	Baseline, 6 month and 12 month
Secondary	Intervention adherence	Measured through electronic diet records and 24 hour dietary recalls	Monthly, through month 6
Secondary	Fasting plasma glucose	From fasting venous blood measured by a commercial lab	Baseline, month 3, month 6, month 9, month 12
Secondary	Plasma cytokines TNF-a, IL-6, IL1-ß, and IL-10, %	Multiplex ELISA	Baseline, month 3, month 6, month 9, month 12
Secondary	Plasma 8-isoprostane	ELISA	Baseline, month 3, month 6, month 9, month 12
Secondary	Colonic mucosa gene expression profiling	Commercially available targeted transcriptomics platform	Baseline, month 6, month 12
Secondary	Ki-67, proliferation	Healthy colonic mucosa, immunohistochemistry	Baseline, month 6, month 12
Secondary	c-caspase-3, Bax, apoptosis	Healthy colonic mucosa, immunohistochemistry,	Baseline, month 6, month 12
Secondary	CD3, CD163, pIKKa/b, tissue markers of inflammation	Healthy colonic mucosa, immunohistochemistry	Baseline, month 6, month 12
Secondary	Weight maintenance (% kg)	Maintenance of weight loss	Month 6 to month 12
Secondary	Fasting plasma insulin	From fasting venous blood measured at a commercial lab	Baseline, month 3, month 6, month 9, month 12
Secondary	HOMA-IR	calculated from fasting glucose and insulin using a standard formula	Baseline, month 3, month 6, month 9, month 12
Secondary	Gut Microbiome	Shotgun metagenomics	Baseline, month 3 and month 6
Secondary	Fecal Metabolites	Untargeted Metabolomics	Baseline, month 3 and month 6
Secondary	Saliva microbiota	Untargeted Metabolomics	Baseline, month 3, month 6